Previous 10 | Next 10 |
2023-06-12 03:54:39 ET Summary Roivant Sciences exhibits a strong financial outlook, backed by its substantial cash position, strategic acquisitions, and efficient R&D expense management. The company's innovative drug pipeline includes the breakthrough product VTAMA for atopic...
2023-05-26 22:25:40 ET Summary Roivant Sciences recently won approval for a topical cream, VTAMA, that looks set to achieve blockbuster (>$1bn per annum) sales. The company has several other highly promising late-stage clinical assets with blockbuster potential, and multiple da...
2023-05-16 07:39:45 ET Dermavant Sciences' Vtama cream met the main goal of achieving clearer skin in a second phase 3 trial to treat adults and pediatric patients down to 2 years old with moderate to severe atopic dermatitis (AD). The trial, dubbed ADORING 1, enrolled 407 children and ...
ADORING 1 met the primary and all secondary endpoints, consistent with the positive topline results from the Phase 3 ADORING 2 trial reported in March, marking Roivant’s 10 th consecutive positive Phase 3 study since 2019 45.4% of subjects receiving VTAMA achieved the primary end...
2023-04-23 16:45:00 ET Last December, Pfizer (NYSE: PFE) essentially out-licensed its tumor necrosis factor-like ligand 1A (TL1A), PF-06480605 (now RVT-3101), to Roivant Sciences (NASDAQ: ROIV) by forming a new company with the precision drugmaker. Per the terms of the deal ...
2023-04-22 16:00:00 ET Treatments for ulcerative colitis (UC) are projected to reach $9.6B in eight major markets by 2031 driven by an increase in the patient population and new therapies coming to market. That's the assessment from data and analytics firm GlobalData, which sees a 2...
2023-04-20 16:29:19 ET Shares of Roivant Sciences (NASDAQ: ROIV) , a pharmaceutical company that specializes in smaller portfolio companies that it calls Vants, were up by 25.3% for the week, as of Thursday afternoon, according to data provided by S&P Global Market Intelli...
2023-04-17 13:55:29 ET Biopharmaceutical stocks were trending higher across the board Monday morning, thanks to Merck 's (NYSE: MRK) nearly $11 billion buyout offer for Prometheus Biosciences (NASDAQ: RXDX) . So far, some of the day's biggest winners have been the cancer...
2023-04-17 08:21:00 ET CNS Pharmaceuticals ( CNSP ) +72% . Presto Automation ( PRST ) +55% . Prometheus Biosciences ( RXDX ) +70% soars 70%, Merck dips after ~$11B buyout deal. Dragonfly Energy ( DFLI ) +49% . Kiromic BioPharma ( ...
2023-04-11 14:35:18 ET On Tuesday, a U.S. appeals court sided with Moderna ( NASDAQ: MRNA ) in a years-long patent dispute between the biotech and Arbutus ( NASDAQ: ABUS ) over messenger-RNA-based COVID vaccine technology. A three-judge panel at the U.S. Court of Appeals...
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Company Name:
ROIV Stock Symbol:
NASDAQ Market:
Roivant Sciences Ltd. Website:
2024-07-11 10:45:04 ET Rivian Automotive Inc (RIVN) RIVN is trading UP for the last 5 days, and it at trading at $16.74 with volume of 18,885,597 and a one day change of $0.37 (2.23%). Rivian Automotive Inc has a 52-week low of 12.15 and a 52-week high of $32.60. The business's 50-d...
2024-06-02 17:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure...